Ntn1 silencing reorganizes the immune cell landscape in the arterial wall, reduces inflammation, increases the expression of M2 marker genes, and upregulates the gene pathways related to phagocytosis and migration in monocytes and TREM2hi macrophages, including the C-C chemokine receptor type 7 signaling pathway required for macrophage migration from plaques and atherosclerosis regression, which suggested that targeting Ntn1 may improve atherosclerotic inflammation and promote plaque regression. The gene discussed is NTN1; the disease is atherosclerosis.